Sugi Predict

Sugi Predict / Compounds / SCHEMBL16554269

SCHEMBL16554269

SCHEMBL16554269

COc1cc(O)ccc1C1CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.53
▸ ESR1 P03372 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ KDM1A O60341 1/20 0.45
▸ MAOA P21397 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CHRNB4 P30926 2/20 0.43
▸ CHRNA3 P32297 2/20 0.43
▸ HTR2C P28335 2/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TAS1R3 Q7RTX0 1/20 0.40
▸ TAS1R1 Q7RTX1 1/20 0.40
▸ TAS1R2 Q8TE23 1/20 0.40
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433301 0.84 ESR2 (0.51) MAOBESR1ESR2KDM1AMAOA
SCHEMBL20923971 0.83 KDM1A (0.68) ESR1ESR2KDM1AMAOAHTR2C
SCHEMBL19097385 0.80 MEN1 (0.62) MAPTMAPK1TDP1CYP3A4MEN1
SCHEMBL23268487 0.78 MEN1 (0.58) HTR2CCYP3A4MEN1KMT2AALDH1A1
SCHEMBL3692141 0.78 MEN1 (0.58) HTR2CCYP3A4MEN1KMT2AALDH1A1
SCHEMBL12180448 0.78 ACHE (0.54) HTR2CCYP3A4MEN1KMT2AALDH1A1
SCHEMBL31172738 0.78 MEN1 (0.58) HTR2CCYP3A4MEN1KMT2AALDH1A1
SCHEMBL16959963 0.78 ALDH1A1 (0.48) MAPTMAPK1HTR2CCYP3A4MEN1
SCHEMBL18757480 0.78 KDM1A (0.54) MAOBESR1ESR2KDM1AMAOA
SCHEMBL16951870 0.78 HTR2C (0.41) MAPTHTR2CCYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
CN-110804072-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
CN-110790789-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 — — US disclosed
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 — — US disclosed
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2022-09-20 — — US disclosed
EP-3572410-B1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2022-07-20 — — EP disclosed
US-20210355106-A1 NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2021-11-18 — — US disclosed
CN-105705510-A Hcv polymerase inhibitors 美迪维尔公司 2016-06-22 — — CN disclosed
WO-2016030335-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2016-03-03 — — WO disclosed
WO-2016030335-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2016-03-03 — — WO disclosed
US-20150175648-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-06-25 — — US disclosed
US-20150175648-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-06-25 — — US disclosed
US-20150175648-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-06-25 — — US disclosed
WO-2015056213-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-04-23 — — WO disclosed
WO-2015056213-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-04-23 — — WO disclosed
WO-2015034420-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-03-12 — — WO disclosed
WO-2015034420-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NT5C MAOB 407/4885ESR1 1065/4885ESR2 1166/4885
US-20210355106-A1 NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM QDPR, QARS1, QPCTL MAOB 934/4885ESR1 2414/4885ESR2 3628/4885
US-20150175648-A1 HCV POLYMERASE INHIBITORS POLI, POLB, POLL MAOB 353/4885ESR1 3422/4885ESR2 3563/4885
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR MAOB 453/4885ESR1 1274/4885ESR2 1220/4885
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR MAOB 453/4885ESR1 1274/4885ESR2 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.